AstraZeneca is hopping aboard the pickleball craze as its serves up a new marketing push for its asthma med Fasenra. More: AstraZeneca embraces pickleball trend with Fasenra tour sponsorship, themed DTC ad Source: fierce
read moreFollowing a hard-fought yet limited FDA approval last year, Akebia plans to kick off a phase 3 trial to assess its Vafseo as a potential treatment for anemia in late-stage CKD patients who aren’t on dialysis. More: Amid Vafseo's US
read moreNovartis has teamed up with the NFL in a multi-year partnership, marking the first such collaboration between the football league and a pharmaceutical company. More: NFL drafts Novartis as league’s first corporate pharma partner Source: fierce
read moreNiemann-Pick disease type C therapy Miplyffa became commercially available in late November and by the year’s end, a total of 109 prescription enrollment forms had been submitted. The company estimates there are around 900 patients with the disease in the
read moreHaving spent the better part of the decade grappling with bankruptcy bids and opioid settlements, troubled drugmakers Mallinckrodt and Endo have decided to join forces to create a more flexible company and ultimately spin off their sizeable generics businesses. More:
read more
EC extends brexpiprazole indication to include adolescents More: Rxulti approved in the European Union for adolescent schizophrenia Source: News
read more© 1994 - 2025 B.M. Pharmaceuticals